Salvage Surgery for Patients With Local Recurrence or Persistent Disease After Treatment With Chemoradiotherapy for SCLC.
Locoregional recurrence
Outcome
Salvage surgery
Small cell lung cancer
Journal
JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
03
03
2021
revised:
28
03
2021
accepted:
01
04
2021
entrez:
30
9
2021
pubmed:
1
10
2021
medline:
1
10
2021
Statut:
epublish
Résumé
The role of salvage surgery for patients with locoregional (LR) recurrence or persistent SCLC after radical chemoradiotherapy (CRT) for limited-stage disease is not well established. We evaluated our experience. We conducted a retrospective study of consecutive patients who underwent salvage pulmonary resection for LR-recurrent or persistent SCLC between 2008 and 2020 at the Amsterdam University Medical Center. A total of 10 patients were identified. Median age at initial diagnosis of limited-stage SCLC was 58.5 years (48-71 y). All patients had radical-intent concurrent CRT. Of the 10 patients, 9 were diagnosed with LR-recurrent or persistent disease with a median of 18 months (3-78 y) after CRT. All patients underwent an anatomical radical resection and mediastinal lymph node dissection. No 90-day mortality was recorded. In addition, one patient developed a LR recurrence 7 months after resection. Distant progression was found in three patients at 6, 32, and 61 months after surgery, all of whom subsequently died of progressive SCLC. Median follow-up was 22.5 months (2-86 mos). Disease-free survival was 34 months; overall survival was not reached. For highly selected patients with LR-recurrent or persistent SCLC after CRT, salvage surgery is feasible and can result in clinically meaningful survival. Such patients should be presented to the multidisciplinary tumor board.
Identifiants
pubmed: 34590022
doi: 10.1016/j.jtocrr.2021.100172
pii: S2666-3643(21)00031-X
pmc: PMC8474289
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100172Informations de copyright
© 2021 The Authors.
Références
Pract Radiat Oncol. 2020 May - Jun;10(3):158-173
pubmed: 32222430
J Thorac Oncol. 2008 Feb;3(2):163-9
pubmed: 18303438
Lung Cancer. 2020 Dec;150:209-215
pubmed: 33220611
J Clin Oncol. 2014 Dec 10;32(35):4012-9
pubmed: 25385727
Jpn J Clin Oncol. 2019 Apr 1;49(4):389-392
pubmed: 30753585
J Thorac Oncol. 2007 Aug;2(8):694-705
pubmed: 17762335
Lung Cancer. 2019 Jul;133:117-122
pubmed: 31200817
Lung Cancer. 2016 Apr;94:108-13
pubmed: 26973215
Jpn J Clin Oncol. 1991 Feb;21(1):39-45
pubmed: 1648633
Lancet Oncol. 2017 Aug;18(8):1116-1125
pubmed: 28642008
J Clin Oncol. 2007 May 20;25(15):2086-92
pubmed: 17513814
Lancet Oncol. 2016 Aug;17(8):1147-1157
pubmed: 27312053
Ther Adv Med Oncol. 2018 Oct 05;10:1758835918804150
pubmed: 30305851
Ann Oncol. 2021 May;32(5):631-641
pubmed: 33539946